Skip to content

AbbVie ABBV Other intangible assets—net

Other intangible assets—net at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$49.06B+33.5%
Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
Cardinal Health logo
Cardinal HealthCAH

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$415B+3.8%
Enterprise value$470.14B+24.7%
P/E114.2×+18.9×
P/S6.6×-0.4×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's other intangible assets—net?
AbbVie (ABBV) reported other intangible assets—net of $50.87B in Q1 2026.
How has AbbVie's other intangible assets—net changed year-over-year?
AbbVie's other intangible assets—net decreased by 13.0% year-over-year, from $58.49B to $50.87B.
What is the long-term trend for AbbVie's other intangible assets—net?
Over 5 years (2020 to 2025), AbbVie's other intangible assets—net has grown at a -8.7% compound annual growth rate (CAGR), from $82.88B to $52.64B.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.